This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Motzer RJ , Rini BI , McDermott DF , Redman BG , Kuzel TM , Harrison MR , Vaishampayan UN , Drabkin HA , George S , Logan TF , Margolin KA , Plimack ER , Lambert AM , Waxman IM , Hammers HJ
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
J Clin Oncol. 2015 May 1;33(13) :1430-7
PMID: 25452452 PMCID: PMC4806782
AbstractPURPOSE: Nivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety. RESULTS: A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, and 4.2 months, respectively (P = .9). Respective ORRs were 20%, 22%, and 20%. Median OS was 18.2 months (80% CI, 16.2 to 24.0 months), 25.5 months (80% CI, 19.8 to 28.8 months), and 24.7 months (80% CI, 15.3 to 26.0 months), respectively. The most common treatment-related adverse event (AE) was fatigue (24%, 22%, and 35%, respectively). Nineteen patients (11%) experienced grade 3 to 4 treatment-related AEs. CONCLUSION: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.
Notes1527-7755 Motzer, Robert J Rini, Brian I McDermott, David F Redman, Bruce G Kuzel, Timothy M Harrison, Michael R Vaishampayan, Ulka N Drabkin, Harry A George, Saby Logan, Theodore F Margolin, Kim A Plimack, Elizabeth R Lambert, Alexandre M Waxman, Ian M Hammers, Hans J P30 CA014236/CA/NCI NIH HHS/United States P30 CA022453/CA/NCI NIH HHS/United States Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't United States J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.